Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
Through ongoing collaboration, new companion diagnostic (CDx) aims to deliver next-generation sequencing results in as little as 24 hours to help advance precision oncology
24 January -- CARLSBAD, Calif.-- (BUSINESS WIRE) -- As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib). The CDx will help identify patients with non-small cell lung cancer (NSCLC) who may be eligible for treatment with Tagrisso by identifying tumors that exhibit epidermal growth factor receptor (EGFR) alterations including exon 21 L858R mutations, exon 19 deletions or T790M mutations.
The collaboration will leverage the Oncomine Dx Express Test* on the Genexus Dx System*, a fully-integrated next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that economically delivers results in as little as 24 hours to bring test results to clinicians and patients faster. NGS-based CDx testing offers the ability to detect multiple biomarkers from a single test, helping to match patients with an appropriate targeted therapy more quickly. The need for faster diagnostic turnaround times was reinforced by research presented at ASCO 2022 that found patients with advanced stage NSCLC had better outcomes, including survival rates, when molecular testing results were available early enough to inform initial treatment decisions.
“As part of our ongoing partnership with AstraZeneca, today’s announcement will help bring targeted oncology treatments to more patients in need of new care options,” said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “By leveraging the Genexus Dx System’s unprecedented turnaround time, we can help ensure molecular testing results are more readily available to inform vital treatment decisions.”
Tagrisso is currently approved in numerous countries and regions around the world for the following indications: the treatment of patients with locally advanced or metastatic EGFR T790M mutation positive NSCLC; the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; and, the adjuvant treatment after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
To learn more about the Oncomine Dx Express Test, please visit www.oncomine.com/express-test
*The Genexus Dx instrument and the Oncomine Dx Express Test are currently available as CE-IVD only
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/d6d18ff8-39d3-4047-b805-cff46eed1dc6.png?optimizer=image&width=360&aspect_ratio=3:4)
bit.bio chooses Automata for automating an aspect of its production of iPSC derived human cells
26th January 2023, London UK – Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC (induced pluripotent stem cell)-derived human cell products.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/1b83c600-5a94-4609-a117-c3cc2e65f43d.png?optimizer=image&width=360&aspect_ratio=3:4)
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
CARLSBAD, Calif.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/b7b6cdbd-5c4c-4ea3-999d-354c99ff80f1.png?optimizer=image&width=360&aspect_ratio=3:4)
rms Company Scales Medical Device Production with Addition of 3D Systems’ DMP Flex 350 Dual
ROCK HILL, South Carolina, January 19, 2023 – Today, 3D Systems (NYSE:DDD) announced rms Company, one of the largest contract manufacturers of high-quality, tight-tolerance medical devices in the world, has added the DMP Flex 350 Dual to its production workflow. rms has more than 30 3D Systems’ DMP 3D printers in its additive manufacturing facility enabling the company to provide a complete Powder to Package capability to medical device OEMs.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/7016459e-99e9-4057-8f3a-9485bf0053fa.png?optimizer=image&width=360&aspect_ratio=3:4)
Ubiquigent and University of Glasgow to collaborate on drug discovery
Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neruodegenerative, renal, and cardiovascular diseases.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/371ef024-65a2-495e-afeb-0b98ffcd9e3a.png?optimizer=image&width=360&aspect_ratio=3:4)
InDevR raises $9 million in series B financing and partners with bioMérieux
Boulder, CO, 17th of January, 2023 – InDevR, Inc., a provider of best-in-class analytical technologies for vaccines and biotherapeutics, announced that it has raised $9 million in series B financing. Adjuvant Capital has invested $4 million, and bioMérieux – a worldwide leader in in vitro diagnostics and microbiological quality control solutions for the food and pharmaceutical industries – $5 million.
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
